Celldex Therapeutics Inc (CLDX) FinancialsCLDXFinancialCelldex Therapeutics Inc

Evaluating the bottom line, Celldex Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -366468.18%, while the net margin is -334104.55%. These profitability ratios, combined with a Return on Equity (ROE) of -43.88%, provide a clear picture of how effectively CLDX converts its operational activities into shareholder value.

In the context of the broader market, CLDX competes directly with industry leaders such as IRON and MBX. With a market capitalization of $3.29B, it holds a leading position in the sector. When comparing efficiency, CLDX's gross margin of 100.00% stands against IRON's N/A and MBX's N/A. Such benchmarking helps identify whether Celldex Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Celldex has shown a gross margin of 100% in recent quarters, but it has also reported substantial net losses, with a net income of -$78.7 million in Q1 2026. This indicates that while the company is generating revenue, it is not yet profitable.